Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01825980 · ClinicalTrials.gov registry record · Phase 1
Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT01825980 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 54 participants.
The verdict
NCT01825980, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
To evaluate the antiviral activity of 3 days of BZF961. To determine safety and tolerability of BZF961 in HCV patients. To evaluate pharmacokinetics of BZF961 in HCV patients.
Interventions
- DRUG Placebo
- DRUG Ritonavir
- DRUG BZF961
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2013-03 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01825980
The ClinicalTrials.gov registry entry for NCT01825980 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01825980 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01825980 about?
NCT01825980 is a clinical study titled "Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients". To evaluate the antiviral activity of 3 days of BZF961. To determine safety and tolerability of BZF961 in HCV patients. To evaluate pharmacokinetics of BZF961 in HCV patients.
What is the current status of trial NCT01825980?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2013-03. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01825980?
The interventions under investigation include: Placebo (DRUG), Ritonavir (DRUG), BZF961 (DRUG).
Who is sponsoring clinical trial NCT01825980?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.